Literature DB >> 7540623

Burkholderia cepacia and cystic fibrosis: do natural environments present a potential hazard?

S L Butler1, C J Doherty, J E Hughes, J W Nelson, J R Govan.   

Abstract

An environmental survey of 55 sites yielded only 12 Burkholderia cepacia isolates, none of which displayed the phenotypic properties of a multiresistant epidemic strain associated with pulmonary colonization in patients with cystic fibrosis. Although the environment probably poses a low risk for patients with cystic fibrosis as a source of B. cepacia, the pathogenic potential of individual environmental strains remains unclear. We advise caution in the development of B. cepacia as a biocontrol agent.

Entities:  

Mesh:

Year:  1995        PMID: 7540623      PMCID: PMC228085          DOI: 10.1128/jcm.33.4.1001-1004.1995

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  31 in total

1.  Pseudomonas cepacia suppression of sunflower wilt fungus and role of antifungal compounds in controlling the disease.

Authors:  T J McLoughlin; J P Quinn; A Bettermann; R Bookland
Journal:  Appl Environ Microbiol       Date:  1992-05       Impact factor: 4.792

2.  Pseudomonas cepacia in inpatients with cystic fibrosis.

Authors:  J W Nelson; C J Doherty; P H Brown; A P Greening; M E Kaufmann; J R Govan
Journal:  Lancet       Date:  1991-12-14       Impact factor: 79.321

3.  Nosocomially acquired Pseudomonas cepacia infection in patients with cystic fibrosis.

Authors:  O C Tablan
Journal:  Infect Control Hosp Epidemiol       Date:  1993-03       Impact factor: 3.254

4.  Pseudomonas cepacia: a new pathogen in patients with cystic fibrosis referred to a large centre in the United Kingdom.

Authors:  E J Simmonds; S P Conway; A T Ghoneim; H Ross; J M Littlewood
Journal:  Arch Dis Child       Date:  1990-08       Impact factor: 3.791

5.  In vitro activities of meropenem, PD 127391, PD 131628, ceftazidime, chloramphenicol, co-trimoxazole, and ciprofloxacin against Pseudomonas cepacia.

Authors:  C Lewin; C Doherty; J Govan
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

6.  Molecular analysis of hemolytic and phospholipase C activities of Pseudomonas cepacia.

Authors:  M L Vasil; D P Krieg; J S Kuhns; J W Ogle; V D Shortridge; R M Ostroff; A I Vasil
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

7.  Pseudomonas cepacia: decrease in colonization in patients with cystic fibrosis.

Authors:  M J Thomassen; C A Demko; C F Doershuk; R C Stern; J D Klinger
Journal:  Am Rev Respir Dis       Date:  1986-10

8.  The identification of Pseudomonas cepacia and its occurrence in clinical material.

Authors:  B Holmes
Journal:  J Appl Bacteriol       Date:  1986-10

9.  Cystic fibrosis in the mouse by targeted insertional mutagenesis.

Authors:  J R Dorin; P Dickinson; E W Alton; S N Smith; D M Geddes; B J Stevenson; W L Kimber; S Fleming; A R Clarke; M L Hooper
Journal:  Nature       Date:  1992-09-17       Impact factor: 49.962

10.  Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis.

Authors:  J J LiPuma; S E Dasen; D W Nielson; R C Stern; T L Stull
Journal:  Lancet       Date:  1990-11-03       Impact factor: 79.321

View more
  30 in total

1.  Molecular method to assess the diversity of Burkholderia species in environmental samples.

Authors:  Joana Falcão Salles; Francisco Adriano De Souza; Jan Dirk van Elsas
Journal:  Appl Environ Microbiol       Date:  2002-04       Impact factor: 4.792

Review 2.  Taxonomy and identification of the Burkholderia cepacia complex.

Authors:  T Coenye; P Vandamme; J R Govan; J J LiPuma
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

3.  Identification of quorum-sensing-regulated genes of Burkholderia cepacia.

Authors:  Claudio Aguilar; Arianna Friscina; Giulia Devescovi; Milan Kojic; Vittorio Venturi
Journal:  J Bacteriol       Date:  2003-11       Impact factor: 3.490

4.  Towards "molecular Esperanto" or the Tower of Babel? (the need for harmonization of techniques for genotyping clinical isolates of Pseudomonas aeruginosa isolated from patients with cystic fibrosis).

Authors:  John E Moore; Colin E Goldsmith; J Stuart Elborn; Philip G Murphy; Peter H Gilligan; Séamus Fanning; Graham Hogg
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

5.  Priming of neutrophil respiratory burst activity by lipopolysaccharide from Burkholderia cepacia.

Authors:  J E Hughes; J Stewart; G R Barclay; J R Govan
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

6.  Transmission of Burkholderia cepacia complex: evidence for new epidemic clones infecting cystic fibrosis patients in Italy.

Authors:  S Campana; G Taccetti; N Ravenni; F Favari; L Cariani; A Sciacca; D Savoia; A Collura; E Fiscarelli; G De Intinis; M Busetti; A Cipolloni; A d'Aprile; E Provenzano; I Collebrusco; P Frontini; G Stassi; M Trancassini; D Tovagliari; A Lavitola; C J Doherty; T Coenye; J R W Govan; P Vandamme
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

7.  Isolation of Burkholderia cepacia by enrichment.

Authors:  P G Flanagan; A Paull
Journal:  J Clin Pathol       Date:  1998-07       Impact factor: 3.411

8.  Comparison of culture and PCR for detection of Burkholderia cepacia in sputum samples of patients with cystic fibrosis.

Authors:  P W Whitby; H L Dick; P W Campbell; D E Tullis; A Matlow; T L Stull
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

9.  Molecular analysis of and identification of antibiotic resistance genes in clinical isolates of Salmonella typhi from India.

Authors:  P M Shanahan; M V Jesudason; C J Thomson; S G Amyes
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

10.  Identification and onion pathogenicity of Burkholderia cepacia complex isolates from the onion rhizosphere and onion field soil.

Authors:  Janette L Jacobs; Anthony C Fasi; Alban Ramette; James J Smith; Raymond Hammerschmidt; George W Sundin
Journal:  Appl Environ Microbiol       Date:  2008-03-14       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.